Recent Updates
Recently added Catalysts
NPCE Positive Sentiment

NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: NeuroPace, Inc. will participate in the Wells Fargo 21st Annual Healthcare Conference. The management team is scheduled for a fireside chat on September 8 at 8:00am EDT and will hold one-on-one meetings with investors. This engagement highlights their commitment to transforming epilepsy treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • NeuroPace is actively engaging with investors.
  • Participation in a prominent healthcare conference.
  • Focus on improving lives of epilepsy patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~39 mo
Minimal dilution risk
Lead asset
external Responsive Neurostimulator System
Phase 2 · Epilepsy

Full Press Release Details

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Tuesday, September 8 at 8:00am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via

Frequently Asked Questions

When will NeuroPace participate in the conference?

NeuroPace will participate in the conference on September 8 at 8:00am EDT.

What is the focus of NeuroPace?

NeuroPace focuses on transforming the lives of people living with epilepsy.

What type of discussions will NeuroPace have at the conference?

NeuroPace management will engage in a fireside chat and one-on-one investor meetings.

ShareAdd on Google
Tags: NPCE Viatris Investor Conferences Healthcare NeuroPace epilepsy healthcare conference investor meetings medical device
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$52M liquidity · $1M/mo burn
~39 mo
Minimal dilution risk
Lead asset
external Responsive Neurostimulator SystemPhase 2
Epilepsy →